Bli medlem
Bli medlem

Du är här

2015-03-28

Novavax, Inc.: Novavax Presents New Data From Non-Human Primate Ebola Challenge at the 7th International Symposium on Filoviruses

GAITHERSBURG, Md., March 28, 2015 (GLOBE NEWSWIRE) --Novavax, Inc.
(Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle vaccines and
adjuvants, today announced Gale Smith, Ph.D., Vice President, Vaccine
Development, will present, "Recombinant EBOV/Makona Glycoprotein (GP)
Nanoparticle Vaccine Produced in Sf9 Insect Cells," at the 7thInternational
Symposium on Filoviruses, Saturday, March 28, 2015 at 10:15 a.m. at the
Washington Marriott Metro Center in Washington, D.C.

As part of his talk, Dr. Smith will present new data from a second non-human
primate (NHP) study which was conducted by the National Institutes of Health,
National Institute of Allergy and Infectious Diseases, Division of
Microbiology and Infectious Diseases (NIH-NIAID-DMID). In that study, animals
received two injections of a 5µg dose of Novavax' Ebola GP Vaccine together
with its proprietary Matrix-M adjuvant and were then challenged with a lethal
dose of the Ebola virus. Similar to the previous NHP study, the challenge was
lethal for the control animals, whereas the animals immunized with Novavax'
EBOV GP Vaccine remain healthy 18 days post challenge.

"This data provides significant, independent confirmation that our Ebola GP
Vaccine is safe and effective in providing protection in NHP models," said
Dr. Smith. "Our vaccine is the first subunit Ebola GP-based vaccine to
provide protection in non-human primates and this confirmatory data strongly
supports the advancement of this program. Importantly, although we developed
our Ebola GP Vaccine from the Makona strain, which is the strain responsible
for the recent Ebola epidemic in West Africa, these primates were challenged
with the Kikwit strain of Ebola, which suggests that our vaccine candidate
may be protective across different variants of the virus."

Novavax is currently conducting a Phase 1 clinical trial of its Ebola GP
Vaccine in healthy subjects. It expects top-line data from this trial in
mid-2015.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases.
Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines. Additional information about Novavax is
available on the company's website,www.novavax.com.

Forward-Looking Statements

Statements contained in this release, including those relating to the closing
of the offering, and those statements using words such as "expects" and
"intends" are forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in the forward-looking statements. These risks and uncertainties include, but
are not limited to: the possible adverse impact on the market price of our
shares of common stock due to the dilutive effect of the securities to be
sold in the offering; our planned use of the proceeds from this offering;
capital market risks; our ability to raise additional capital when needed;
and other risk factors identified from time to time in the reports we file
with Securities and Exchange Commission (SEC), including our Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K,
which are available at
www.sec.gov. We caution investors not to place considerable reliance on the
forward-looking statements contained in this press release. You are
encouraged to read our filings with the SEC, available at sec.gov, for a
discussion of these and other risks and uncertainties. The forward-looking
statements in this press release speak only as of the date of this document,
and we undertake no obligation to update or revise any of the statements. Our
business is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.

CONTACT: Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com

240-268-2000

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire

HUG#1907151

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.